


THE JOURNEY OF AN ANIMAL HEALTH START-UP




PetMedix founder, Prof Allan Bradley FRS, publishes complete humanization of the mouse immunoglobulin loci.

2014



PetMedix founder, Dr Jolyon Martin, publishes first comprehensive annotation of canine immunoglobulin loci.



Formation of PetMedix as a company

2017



2018



Completion of PhD project adapting the transgenic platform from human to canine

JANUARY 2019

2019



Size of company: 12 staff





APRIL 2019

FEBRUARY 2019




Shortlisted to present at the Animal Health Investment Europe Innovation Showcase

£8million Series A funding secured



Dr Fabian Kausche and Dr Cindy Cole join the Board of Directors

DECEMBER 2019



Dr Dave Lowery joins the company

JANUARY 2020

2020



Size of company: 24 staff

Establishment of PetMedix Inc. our US business entity


Judged as 'One to Watch' in the global Nature Spinoff Awards

FEBRUARY 2020



Animal Pharm 'Best Start-up 2019' award winner

OCTOBER 2020



Size of company: 32 staff

APRIL 2020



Move to Babraham Research Campus

Canine platform developed for therapeutic antibody discovery

Feline platform under development

MAY 2020



Funding from Cambridge Innovation Capital secured

Development underway of a pipeline of internal assets

Series B fundraise underway

FUTURE

2021




In vivo testing of first PetMedix assets

2021-2023



Expansion of PetMedix pipeline, including feline drug discovery

2024



Pivotal studies and regulatory filings underway

THE PETMEDIX JOURNEY



The animal health market has, until recently, been dominated by large pharmaceutical companies with in-house R&D contributing the majority of new developments. More recently, the industry has followed the path of in the human health sector, with increasing numbers of independent start-up companies innovating new solutions in every area of animal health.

PetMedix is one such company, spinning out of the University of Cambridge and applying the principles of One Health to translate cutting-edge human health technologies to benefit companion animals. Founded in 2018, following on from a PhD project in Professor Allan Bradley's lab, co-founder Dr Jolyon Martin put the groundwork in to develop a transgenic monoclonal antibody platform for the development of precision canine therapeutics.

In a little over a year from inception, the PetMedix team successfully secured £8 million series A funding in February 2019. They had also made it on to the shortlist to present at the Kisaco Animal Health Showcase at the Innovation Showcase. The showcase was developed to give smaller companies pushing towards advancements in animal health, such as PetMedix, the platform to connect their team, technology and business strategy with investors and key opinion leaders. This valuable networking opportunity helps to drive the direction and growth of smaller companies, while opening the door for partnering opportunities and investment.

Kisaco Research

Kisaco has continued to develop a good relationship with the PetMedix team, inviting them to speak at events and facilitating networking opportunities. Since their first Kisaco meeting in London, in 2018, PetMedix have attended a total of seven Kisaco events worldwide. The opportunity to present and network at events globally opens the door to accessing expertise, investment and market opportunities around the world. PetMedix have embraced the global nature of animal health, engaging with investors and stakeholders in Asia – in addition to Europe and the US – at Kisaco events.

By Spring of 2019, PetMedix board had welcomed the additional expertise of Dr Fabian Kausche and Dr Cindy Cole. Both qualified veterinarians with extensive experience in animal health R&D, they bring a wealth of knowledge and strategy to the team. The company also moved into new labs in the heart of the Cambridge biotech cluster in May. This highly sought after, prime lab space enabled the growth of the scientific team with a number of PhD level hires, and the purchase of new equipment as platform development progressed.

Later in 2019, PetMedix further boosted their in-house R&D expertise welcoming Dr Dave Lowery to the team as Chief Product Development Officer. Dr Lowery has over 30 years of leadership experience in the Animal Health industry, including the last decade bringing modern antibody-based drugs to the Animal Health market. With knowledge of both the UK and US animal health markets across the senior management team, PetMedix are well set up to take their technology global.

The year was rounded off by the announcement PetMedix was awarded 'Best Start-up 2019' in the Animal Pharm Awards. The awards aim to highlight innovation and growth made by companies of all sizes and from different sectors.

Joseph Harvey, Editor of Animal Pharm, said:

"The company's submission was very impressive – full of information that clearly stated its achievements so far and its intentions. It was a worthy winner in this category."

Despite the global challenges in 2020, PetMedix maintained a strong growth trajectory. The expanding team moved into brand new premises in April at the Babraham Research Campus, Cambridge UK. The move highlighted the outstanding attitude and adaptability of the team in completing an agile and successful transfer, and resulted in the donation of surplus equipment to the NHS.

Additional Series A+ funding from Cambridge Innovation Capital was secured shortly after the move. This paved the way for commencement of activities in the US with the formation of PetMedix subsidiary stateside.

Dr. Tom Weaver, CEO, said at the time:

"We have the people and the technology in place, and are champing at the bit to progress these therapies to reach the pets that could benefit. We know this technology has transformed the treatment and survival of human patients with a variety of conditions and we want to create the same paradigm shift in veterinary treatment options to improve welfare, quality of life and longevity for our dogs and cats."

Further recognition of the stand-out progress of the company followed with PetMedix being singled out as 'One to Watch' in the global Nature Spinoff awards, which recognise excellence in the commercialisation of research through the creation of university spinoff companies. The judges look for spinoffs that translate original, high-quality scientific research into products and services that address market problems and are well positioned to make a positive impact on society. The positive impact of the therapeutics PetMedix are developing is not simply confined to the dogs and cats which may benefit, currently woefully underserved by precision medication, but also to their owners. Pets are increasingly recognised as important and valued members of the family and integral to the mental and physical health of their human counterparts.

Today, PetMedix employ a team of over 30, with many PhD level scientists. Their Ky9™ transgenic monoclonal platform is being used for drug discovery, and development of the Felyne™ platform is well underway. Drug discovery is progressing, with identification and development of the lead asset alongside work on identifying new targets to develop in parallel. The company is currently launching their series B funding round and exploring partnership opportunities.

The future looks bright for this relatively young company are on course to see their first drug on the veterinary pharmacy shelves in 2024.

PetMedix Co-founder, Dr Jolyon Martin, comments:

"We are delighted with our progress

to date. Our platforms continue to evolve and drug discovery is well underway, along with our ambition to build a world-class animal health company. The opportunity to showcase our technology and network globally has been greatly helped through our relationship with Kisaco. They have responded to the trend towards smaller start-ups increasingly contributing to innovations in the animal health space, and provide an important platform for companies, like us, to reach a wide audience and access both funding and expertise from around the world."